In 2008, Nassim Taleb and I wrote a commentary for the Financial Times arguing that the fundamental reason new drug development hadn’t lived up to the expectations of the genomics revolution was “the mismeasure of uncertainty, as academic researchers underestimated the fragility of scientific knowledge, and pharmaceutical executives overestimated their ability to domesticate scientific research,” [...] Read More...
Filed under: health, Pharma & Healthcare, Innovation & Science, byline=David Shaywitz, Strategies & Solutions, Business, Food and Drug Administration, drug development, Novartis, Rare disease, Canakinumab, ticker=NYSE:NVS, Financial Times